This database contains 472 studies, archived under the term: "Pharmaceutical Interventions"
Click here to filter this large number of results.
Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin
Endres, Kristina,
Fahrenholz, Falk,
Lotz, Johannes,
Hiemke, Christoph,
Teipel, Stefan,
Lieb, Klaus,
Tüscher, Oliver,
Fellgiebel, Andreas
Objective: We investigated induction of α-secretase A disintegrin and metalloprotease 10 (ADAM10) by the synthetic retinoid acitretin (Neotigason; Actavis, München-Riem, Germany) in patients with mild to moderate Alzheimer disease (AD) via measurement of CSF content of α-secretase-derived amyloid precursor protein (APPs-α).; Methods: Twenty-one patients clinically diagnosed with mild to moderate AD received acitretin (30 mg […]
Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial
Cooper, Sally-Ann,
Caslake, Muriel,
Evans, Jonathan,
Hassiotis, Angela,
Jahoda, Andrew,
McConnachie, Alex,
Morrison, Jill,
Ring, Howard,
Starr, John,
Stiles, Ciara,
Sullivan, Frank
Background: Early-onset dementia is common in Down syndrome adults, who have trisomy 21. The amyloid precursor protein gene is on chromosome 21, and so is over-expressed in Down syndrome, leading to amyloid β (Aβ) over-production, a major upstream pathway leading to Alzheimer disease (AD). Statins (microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), have pleiotropic effects including […]
Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
Emre, Murat,
Tsolaki, Magda,
Bonuccelli, Ubaldo,
Destée, Alain,
Tolosa, Eduardo,
Kutzelnigg, Alexandra,
Ceballos-Baumann, Andrés,
Zdravkovic, Slobodan,
Bladström, Anna,
Jones, Roy
Background: Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB).; Methods: Patients (≥50 years […]
Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET)
Drye, Lea T.,
Scherer, Roberta W.,
Lanctôt, Krista L.,
Rosenberg, Paul B.,
Herrmann, Nathan,
Bachman, David,
Mintzer, Jacobo E.
Background: Research on efficacious treatments for apathy in Alzheimer disease has been hindered by a lack of consensus diagnosis, difficulties in measurement, and studies with small sample sizes.; Methods: In designing the Apathy in Dementia Methylphenidate Trial (ADMET), a trial to evaluate the efficacy and safety of methylphenidate for the treatment of apathy in Alzheimer […]
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer’s disease
Gillette-Guyonnet, Sophie,
Andrieu, Sandrine,
Dantoine, Thierry,
Dartigues, Jean-François,
Touchon, Jacques,
Vellas, B.
Background: Because no effective curative approaches are available, preventive approaches in the field of Alzheimer’s disease (AD) are needed. We present the design of the ongoing Multidomain Alzheimer Preventive Trial (MAPT) Study. Several previous studies suggested that many factors may be involved in the occurrence of AD at late ages. Because of the probable multifactorial […]
Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial
Culo, Sandi,
Mulsant, Benoit H.,
Rosen, Jules,
Mazumdar, Sati,
Blakesley, Richard E.,
Houck, Patricia R.,
Pollock, Bruce G.
Sensitivity to psychotropic medications presents a therapeutic challenge when treating neuropsychiatric symptoms in patients with dementia with Lewy bodies (DLB). We compared under randomized, double-blinded conditions the tolerability and efficacy of citalopram and risperidone in the treatment of behavioral and psychotic symptoms in patients with DLB and Alzheimer disease (AD). Thirty-one participants with DLB and […]
Acute caffeine administration effect on brain activation patterns in mild cognitive impairment
Haller, Sven,
Montandon, Marie-Louise,
Rodriguez, Cristelle,
Moser, Dominik,
Toma, Simona,
Hofmeister, Jeremy,
Sinanaj, Indrit,
Lovblad, Karl-Olof,
Giannakopoulos, Panteleimon
Previous studies showed that acute caffeine administration enhances task-related brain activation in elderly individuals with preserved cognition. To explore the effects of this widely used agent on cognition and brain activation in early phases of cognitive decline, we performed a double-blinded, placebo-controlled functional magnetic resonance imaging (fMRI) study during an n-back working memory task in […]
Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson’s disease
Li, Wei,
Zhao, Jian-Hua,
Sun, Sheng-Gang,
Zhang, Jie-Wen,
Suo, Ai-Qin,
Ma, Ming-Ming
Objective: To study the effects of memantine on cognitive and motor impairment in patients with Parkinson’s disease (PD).; Methods: A total of 55 PD patients complicated by varying degrees of cognitive impairment were randomly divided into two groups. The patients of experimental group (n = 28) received memantine (20 mg/d) while those in the control […]